Measuring AHSP in blood as a marker in sickle cell disease
Measures AHSP levels in blood of children and adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"
Key facts
- Where
- Saint-Denis, FranceSee the site
Where in France
- Centre Hospitalier de Saint-DenisSaint-Denis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier de Saint-Denis
- Trial code
- NCT06735625
- Record updated
- 2 April 2025
- Original description
Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patientsRead full original descriptionShow less
Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"
Evaluation of AHSP concentration in total blood as a biomarker in adult and pediatric sickle cell patients
Inclusion: Adults: > 15 years and 6 months; Pediatrics: ≥ 3 years and ≤ 15 years and 6 months; Known SS or Sβ0 phenotypes; 1 -Adults: > 15 years and 6 months /Pediatrics: ≥ 3 years and ≤ 15 years and 6 months 2-Absence of Hemoglobinopathy 3-Follow-up for one of the following conditions (adults): Evaluation of hematological disease excluding hemoglobinopathy, evaluation of prolonged fever or inflammatory syndrome, initial or episodic evaluation of an auto-inflammatory disease or systemic disease, general health deterioration; -Follow-up for one of the following conditions (pediatrics): Suspected precocious puberty, growth delay, or neurodevelopmental disorder; 4-Blood sample planned as part of medical care.
Exclusion: Known hyper or hypothyroidism or subject treated with levothyroxine; Oral corticosteroid therapy in progress; Hemoglobinopathies other than sickle cell disease (Criteria for Control Patients); Chronic active viral disease: hepatitis B, C, HIV; Current infections or known inflammatory pathologies; Hemoglobin disorder other than sickle cell disease (Criteria for Sickle Cell Patients); Transfusion less than 3 months ago; Active tumor pathology or remission for less than 5 years; Participation in interventional biomedical research; Opposition to participation in research by the patient if he is an adult, or by one of the two parents if the patient is a minor; Non-affiliation to a social security system.